Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
Adherent lymphokine-activated killer (A-LAK) activity has been recently differentiated in recombinant interleukin-2 (rIL-2) activated PBL. A pilot study on A-LAK + rIL-2 injection into the post-surgical cavity of glioblastoma-operated patients is ongoing. Preliminary data support the feasibility of this technique, which may improve the antitumor response of the host.
Munari
L
L
Istituto Nazionale Neurologico C. Besta, Milano, Italy.
Silvani
A
A
Passerini
C G
CG
Radrizzani
M
M
Parmiani
G
G
Boiardi
A
A
D000328:Adult; D001932:Brain Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins